Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD
Epistemonikos ID: 3c05bbe11e00ed055b02b1a96ab6506659629f84
First added on: May 21, 2024